TG Therapeutics, Inc. Q3 2025 Earnings Recap

TGTX Q3 2025 November 5, 2025

Get alerts when TGTX reports next quarter

TG Therapeutics reported robust Q3 2025 results, highlighted by impressive sales growth for BRIUMVI, which continues to outperform market expectations. The company remains committed to innovation and disciplined financial management.

Earnings Per Share Beat

$2.43 vs $0.24 est.

+912.5% surprise

Revenue Miss

161709000 vs 193801630 est.

-16.6% surprise

Market Reaction

1-Day -2.29%

5-Day -8.9%

30-Day -9.43%

See TGTX alongside your other holdings

Add to your portfolio — free

Key Takeaways

BRIUMVI generated approximately $153 million in U.S. net sales for Q3, exceeding internal targets and market forecasts.
Enrollment in pivotal studies for a simplified dosing schedule and subcutaneous ublituximab is progressing well, with potential launches anticipated in 2027 and 2028, respectively.
The recently completed $100 million share repurchase program and an additional authorized program reflect TG's commitment to returning capital to shareholders.
Continued strong demand and physician engagement for BRIUMVI highlight the growing preference for anti-CD20 therapies in MS treatment.
Intermediate data reveals significant efficacy and safety of BRIUMVI, with 90% of patients remaining free from disability progression after six years of treatment.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit TGTX on AllInvestView.